Abstract
As melanoma cells are present in the circulation of many patients with this cancer, decreases in their number could provide an early indication of therapy effectiveness. To evaluate this possibility, we examined the effect of treatment with a melanoma vaccine on the number of melanoma cells present in the circulation. PCR was used to detect melanoma cells that expressed the melanoma-associated antigens MART-1, MAGE-3, tyrosinase and/or gp100 in 91 patients with melanoma. Melanoma cells that expressed one or more of these markers were present more often in advanced disease, i.e. in 80% of patients with advanced stage IV compared to in less than one-third of patients with less advanced disease. We then measured circulating melanoma cells in a subset of 43 of these patients who were treated with a polyvalent, shed antigen, melanoma vaccine. The vaccine contains multiple melanoma-associated antigens including MART-1, MAGE-3, tyrosinase and gp100. Immunizations were given intradermally q2–3 weeks ×4 and then monthly ×3. Prior to vaccine treatment, circulating melanoma cells were detected in 14 (32%) patients. Following 4 and 7 months of vaccine treatment, melanoma cells that expressed any of these markers were present in only nine (21%) and three (7%) of patients, respectively. Thus, vaccine therapy was associated with clearance of melanoma cells from the circulation in 78% of initially positive patients. As the number of these cells declined steadily with increasing length of therapy, it is unlikely that this was due to a random change in their number. Rather it suggests that the decline was a result of the therapy.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bystryn J-C, Jacobsen S, Harris M, Roses D, Speyer J, Levin M. Preparation and characterization of a polyvalent human melanoma antigen vaccine. J Biol Resp Modif 5: 211–224, 1986
Gershman N, Johnston D, Bystryn J-C. Potentiation of B16 melanoma vaccine immunogenicity by IL-2 liposomes. Vaccine Res 3 (2): 83–92, 1994
Reynolds Sr, Oratz R, Shapiro RL, Fotino M, Hao P, Vukmanovic S, Bystryn J-C. Stimulation of CD8+ T cell responses to MAGE-3 and MELAN A/MART-1 by immunization to a polyvalent melanoma vaccine. Int J Cancer 72: 972–976, 1997.
Reynolds Sr, Celis E, Sette A, Oratz R, Shapiro RL, Johnston D, Fotino M, Bystryn J-C. HLA-independent heterogeneity of CD8+ T cell responses to MAGE-3, Melan A/MART-1, gp100, tyrosinase, MC1R and TRP-2 in vaccine-treated melanoma patients. J Immunol 161: 6970–6976, 1998.
Bystryn J-C, Shapiro RL, Oratz R. Cancer vaccines: Clinical applications: Partially purified tumor antigen vaccines. In: Biologic Therapy of Cancer, 2nd Edition, ed by V DeVita, S Hellman and SA Rosenberg; JB Lippincott:Philadelphia, pp 668–679, 1995
Bystryn J-C, Oratz R, Shapiro RL, Harris MN, Roses DF, Zeleniuch-Jacquotte A, Chen Dl, Rivas MC. Double-blind, placebo-controlled, trial of a shed, polyvalent, melanoma vaccine in stage III melanoma. Proc Am Soc Clin Oncol 434 (1673), 1999
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2001 Springer-Verlag Berlin · Heidelberg
About this paper
Cite this paper
Bystryn, JC. et al. (2001). Decrease in Circulating Tumor Cells as an Early Marker of Therapy Effectiveness. In: Reinhold, U., Tilgen, W. (eds) Minimal Residual Disease in Melanoma. Recent Results in Cancer Research, vol 158. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-59537-0_21
Download citation
DOI: https://doi.org/10.1007/978-3-642-59537-0_21
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-64015-5
Online ISBN: 978-3-642-59537-0
eBook Packages: Springer Book Archive